Dihydroartemisinin Inhibits Epithelial–Mesenchymal Transition Progression in Medullary Thyroid Carcinoma Through the Hippo Signaling Pathway Regulated by Interleukin-6
Cancer Biotherapy and Radiopharmaceuticals · 2025
DOI: 10.1089/cbr.2023.0197 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Biotherapy and Radiopharmaceuticals, 2025. Verfasst von Ruicong Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, Hebei Medical University, 050017, Shijiazhuang, China. Hauptthemen laut MEDLINE: Artemisinins, Epithelial-Mesenchymal Transition, Interleukin-6, Thyroid Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Dihydroartemisinin (DHA), an artemisinin derivative, can influence certain malignancies’ inflammatory response and growth. This study used Cell Counting Kit-8 and Transwell assays to show that DHA suppressed the growth, migration, and invasion of medullary thyroid cancer cells. Furthermore, the authors used enzyme-linked immunosorbent assay, Western blotting, and immunofluorescence to confirm the expression of the transcriptional coactivators Yes-associated protein (YAP)/transcriptional coactivator with a PDZ-binding domain (TAZ) downstream of the Hippo pathway and changes in the expression of the epithelial–mesenchymal transition (EMT) process markers E-cadherin and N-cadherin. These results demonstrate that DHA effectively reduced the expression of interleukin (IL)-6 in medullary thyroid carcinoma (MTC) cells and hindered the EMT process by regulating the Hippo pathway. This regulation was achieved by promoting YAP phosphorylation and inhibiting YAP/TAZ protein expression. Additional activation of the Hippo pathway by GA-017 alleviated the inhibitory effect of DHA on IL-6. Hippo pathway activation led to an increase in the expression of E-cadherin, a marker of EMT. In conclusion, DHA was demonstrated to regulate the Hippo pathway by inhibiting IL-6 secretion, leading to the inhibition of EMT in MTC. These findings provide a theoretical foundation for further exploration of the anticancer mechanisms of DHA and offer valuable insights into its potential clinical application as a combinatorial drug.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology, Hebei Medical University, 050017, Shijiazhuang, China.
- Department of Otolaryngology Head and Neck Surgery, The Fourth Hospital of Hebei Medical University and Hebei Provincial Tumor Hospital, Shijiazhuang, 050011, China.
- Department of Otolaryngology, Baoding No. 1 Central Hospital, 071000, Baoding, China.
- Department of Otolaryngology, The Second Hospital of Shijiazhuang, 050057, Shijiazhuang, China.
- Department of General Surgery, Luquan People's Hospital, 050200, Shijiazhuang, China.
- Department of Otolaryngology Head and Neck Surgery, The 980th Hospital of the PLA Joint Logistics Support Force, 050082, Shijiazhuang, China.
ORCID-Profile: Xiaoming Li
Zitieren
APA
Li, R., Zhang, X., Ge, Y., Zhao, Z., Feng, L., & Li, X. (2025). Dihydroartemisinin Inhibits Epithelial–Mesenchymal Transition Progression in Medullary Thyroid Carcinoma Through the Hippo Signaling Pathway Regulated by Interleukin-6. Cancer Biotherapy and Radiopharmaceuticals. https://doi.org/10.1089/cbr.2023.0197
Vancouver
Li R, Zhang X, Ge Y, Zhao Z, Feng L, Li X. Dihydroartemisinin Inhibits Epithelial–Mesenchymal Transition Progression in Medullary Thyroid Carcinoma Through the Hippo Signaling Pathway Regulated by Interleukin-6. Cancer Biotherapy and Radiopharmaceuticals. 2025. doi:10.1089/cbr.2023.0197
BibTeX
@article{Li2025,
author = {Li, Ruicong and Zhang, Xinyu and Ge, Yanan and Zhao, Zhen and Feng, Liangliang and Li, Xiaoming},
title = {Dihydroartemisinin Inhibits Epithelial–Mesenchymal Transition Progression in Medullary Thyroid Carcinoma Through the Hippo Signaling Pathway Regulated by Interleukin-6},
journal = {Cancer Biotherapy and Radiopharmaceuticals},
year = {2025},
doi = {10.1089/cbr.2023.0197}
}
EUVIMED